Literature DB >> 21734248

Pathogenesis and pathophysiology of pneumococcal meningitis.

Barry B Mook-Kanamori1, Madelijn Geldhoff, Tom van der Poll, Diederik van de Beek.   

Abstract

Pneumococcal meningitis continues to be associated with high rates of mortality and long-term neurological sequelae. The most common route of infection starts by nasopharyngeal colonization by Streptococcus pneumoniae, which must avoid mucosal entrapment and evade the host immune system after local activation. During invasive disease, pneumococcal epithelial adhesion is followed by bloodstream invasion and activation of the complement and coagulation systems. The release of inflammatory mediators facilitates pneumococcal crossing of the blood-brain barrier into the brain, where the bacteria multiply freely and trigger activation of circulating antigen-presenting cells and resident microglial cells. The resulting massive inflammation leads to further neutrophil recruitment and inflammation, resulting in the well-known features of bacterial meningitis, including cerebrospinal fluid pleocytosis, cochlear damage, cerebral edema, hydrocephalus, and cerebrovascular complications. Experimental animal models continue to further our understanding of the pathophysiology of pneumococcal meningitis and provide the platform for the development of new adjuvant treatments and antimicrobial therapy. This review discusses the most recent views on the pathophysiology of pneumococcal meningitis, as well as potential targets for (adjunctive) therapy.

Entities:  

Mesh:

Year:  2011        PMID: 21734248      PMCID: PMC3131058          DOI: 10.1128/CMR.00008-11

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  554 in total

1.  Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis.

Authors:  S L Leib; D Leppert; J Clements; M G Täuber
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models.

Authors:  Carlos J Orihuela; Jafar Mahdavi; Justin Thornton; Beth Mann; Karl G Wooldridge; Noha Abouseada; Neil J Oldfield; Tim Self; Dlawer A A Ala'Aldeen; Elaine I Tuomanen
Journal:  J Clin Invest       Date:  2009-05-11       Impact factor: 14.808

3.  Human brain pericytes as a model system to study the pathogenesis of cerebrovascular amyloidosis in Alzheimer's disease.

Authors:  M M Verbeek; I Otte-Höller; D J Ruiter; R M de Waal
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  1999-02       Impact factor: 1.770

4.  Surface bound plasmin promotes migration of Streptococcus pneumoniae through reconstituted basement membranes.

Authors:  T Eberhard; G Kronvall; M Ullberg
Journal:  Microb Pathog       Date:  1999-03       Impact factor: 3.738

5.  In vivo binding of complement regulator factor H by Streptococcus pneumoniae.

Authors:  Lisa R Quin; Stephanie Carmicle; Sandhya Dave; Michael K Pangburn; Jason P Evenhuis; Larry S McDaniel
Journal:  J Infect Dis       Date:  2005-10-26       Impact factor: 5.226

6.  Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance.

Authors:  Aaron L Nelson; Aoife M Roche; Jane M Gould; Kannie Chim; Adam J Ratner; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2006-11-06       Impact factor: 3.441

7.  Interferon-gamma in cerebrospinal fluid from patients with viral and bacterial meningitis.

Authors:  M Glimåker; P Olcén; B Andersson
Journal:  Scand J Infect Dis       Date:  1994

8.  Production of nitrite by primary rat astrocytes in response to pneumococci.

Authors:  A Bernatowicz; U Ködel; K Frei; A Fontana; H W Pfister
Journal:  J Neuroimmunol       Date:  1995-07       Impact factor: 3.478

9.  The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms.

Authors:  Catherine Hyams; Emilie Camberlein; Jonathan M Cohen; Katie Bax; Jeremy S Brown
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

10.  Immunological and biochemical correlates of adjunctive dexamethasone in Vietnamese adults with bacterial meningitis.

Authors:  Nguyen Thi Hoang Mai; Trung Vu Tuan; Marcel Wolbers; Dang Minh Hoang; Tran Vu Thieu Nga; Tran Thi Hong Chau; Ly Van Chuong; Dinh Xuan Sinh; Ho Dang Trung Nghia; Nguyen Duy Phong; Nguyen Hoan Phu; To Song Diep; Hoang Thi Thanh Hang; Nguyen van Vinh Chau; Jeremy Farrar; Constance Schultsz; Tran Tinh Hien; Cameron P Simmons
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079

View more
  151 in total

1.  Chiasmal optic neuritis may be secondary to pneumococcal meningitis: a child with acute monocular vision loss.

Authors:  Sevim Şahin; Mehmet Kola; Ali Cansu; Sibel Kul; Halil İbrahim İmamoğlu
Journal:  Neurol Sci       Date:  2015-09-05       Impact factor: 3.307

2.  Free Sialic Acid Acts as a Signal That Promotes Streptococcus pneumoniae Invasion of Nasal Tissue and Nonhematogenous Invasion of the Central Nervous System.

Authors:  Brandon L Hatcher; Joanetha Y Hale; David E Briles
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

3.  Association between Experimental Bacterial Meningitis and Periapical Lesion.

Authors:  Tatiana Barichello; Soraia Netto; Renan Antonio Ceretta; Jaqueline S Generoso; Lutiana R Simões; Patrícia Ávila Ribeiro; Josiane Budni; João Quevedo
Journal:  J Clin Diagn Res       Date:  2015-05-01

4.  Diagnostic Accuracy of Peripheral White Blood Cell Count, Fever and Acute Leukocutosis for Bacterial Meningitis in Patients with Severe Traumatic Brain Injury.

Authors:  Hosseinali Khalili; Golnaz YadollahiKhales; Mohammad Isaee
Journal:  Bull Emerg Trauma       Date:  2015-04

5.  Heterologous prime-boost immunization with live SPY1 and DnaJ protein of Streptococcus pneumoniae induces strong Th1 and Th17 cellular immune responses in mice.

Authors:  Yulan Qiu; Xuemei Zhang; Hong Wang; Xinyuan Zhang; Yunjun Mo; Xiaoyu Sun; Jichao Wang; Yibing Yin; Wenchun Xu
Journal:  J Microbiol       Date:  2017-09-28       Impact factor: 3.422

6.  Invasive pneumococcal disease in children can reveal a primary immunodeficiency.

Authors:  Jean Gaschignard; Corinne Levy; Maya Chrabieh; Bertrand Boisson; Cécile Bost-Bru; Stéphane Dauger; François Dubos; Philippe Durand; Joël Gaudelus; Dominique Gendrel; Christèle Gras Le Guen; Emmanuel Grimprel; Gaël Guyon; Catherine Jeudy; Eric Jeziorski; Francis Leclerc; Pierre-Louis Léger; Fabrice Lesage; Mathie Lorrot; Isabelle Pellier; Didier Pinquier; Loïc de Pontual; Philippe Sachs; Caroline Thomas; Pierre Tissières; Frédéric V Valla; Philippe Desprez; Véronique Frémeaux-Bacchi; Emmanuelle Varon; Xavier Bossuyt; Robert Cohen; Laurent Abel; Jean-Laurent Casanova; Anne Puel; Capucine Picard
Journal:  Clin Infect Dis       Date:  2014-04-23       Impact factor: 9.079

7.  Genetic diversity of the Pneumococcal CbpA: Implications for next-generation vaccine development.

Authors:  Muna F Abry; Kelvin M Kimenyi; Fred O Osowo; Willingtone O Odhiambo; Steven O Sewe; Benard W Kulohoma
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Tryptophan catabolism reflects disease activity in human tuberculosis.

Authors:  Jeffrey M Collins; Amnah Siddiqa; Dean P Jones; Ken Liu; Russell R Kempker; Azhar Nizam; N Sarita Shah; Nazir Ismail; Samuel G Ouma; Nestani Tukvadze; Shuzhao Li; Cheryl L Day; Jyothi Rengarajan; James Cm Brust; Neel R Gandhi; Joel D Ernst; Henry M Blumberg; Thomas R Ziegler
Journal:  JCI Insight       Date:  2020-05-21

9.  Edaravone attenuates hippocampal damage in an infant mouse model of pneumococcal meningitis by reducing HMGB1 and iNOS expression via the Nrf2/HO-1 pathway.

Authors:  Zheng Li; Qian-Qian Ma; Yan Yan; Feng-Dan Xu; Xiao-Ying Zhang; Wei-Qin Zhou; Zhi-Chun Feng
Journal:  Acta Pharmacol Sin       Date:  2016-08-29       Impact factor: 6.150

10.  Pneumococcal Neuraminidase Substrates Identified through Comparative Proteomics Enabled by Chemoselective Labeling.

Authors:  Janet E McCombs; Jennifer J Kohler
Journal:  Bioconjug Chem       Date:  2016-03-22       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.